Myalept
About Myalept
Leptin replacement therapy is offered by Myalept in the pharmaceutical sector for treating generalized lipodystrophy. The prescription medication addresses leptin hormone deficiency and is administered with a physician-guided diet to manage related health issues. Additional services include nutritional counseling and insurance navigation. Access is controlled through a restricted distribution program for eligible prescribers. Side effects are documented, with healthcare provider consultation recommended for patients.
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Myalept
Detailed funding history for Myalept
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Myalept
Myalept has secured backing from 1 investor. Prominent investors backing the company include Aegerion.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Locked | Locked | Locked |
Investor details for Myalept
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Myalept
Investment portfolio details for Myalept
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Myalept
Detailed financials for Myalept
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Myalept Comparisons
Peer comparison for Myalept
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Myalept
Detailed competitors of Myalept
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Myalept
Complete news archive for Myalept
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Myalept
Leptin replacement therapy is offered by Myalept in the pharmaceutical sector for treating generalized lipodystrophy. The prescription medication addresses leptin hormone deficiency and is administered with a physician-guided diet to manage related health issues. Additional services include nutritional counseling and insurance navigation. Access is controlled through a restricted distribution program for eligible prescribers. Side effects are documented, with healthcare provider consultation recommended for patients.
Myalept has 1 investor. Key investors include Aegerion.